A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease
Language English Country United Arab Emirates Media print
Document type Journal Article, Systematic Review
PubMed
29768996
DOI
10.2174/0929867325666180517094023
PII: CMC-EPUB-90497
Knihovny.cz E-resources
- Keywords
- Alzheimer’s disease, NMDA, acetylcholinesterase, butyrylcholinesterase, donepezil, inhibitor, treatment.,
- MeSH
- Acetylcholinesterase metabolism MeSH
- Alzheimer Disease drug therapy metabolism MeSH
- Butyrylcholinesterase metabolism MeSH
- Cholinesterase Inhibitors chemistry pharmacology therapeutic use MeSH
- Donepezil chemistry pharmacology therapeutic use MeSH
- Humans MeSH
- Molecular Structure MeSH
- Neuroprotective Agents chemistry pharmacology therapeutic use MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Systematic Review MeSH
- Names of Substances
- Acetylcholinesterase MeSH
- Butyrylcholinesterase MeSH
- Cholinesterase Inhibitors MeSH
- Donepezil MeSH
- Neuroprotective Agents MeSH
Alzheimer's Disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden. This review presents the overview of donepezilrelated compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.
References provided by Crossref.org
